Neem Biotech, an Abertillery based R&D pharmaceutical biotech company working to combat antimicrobial resistance using non-traditional antibiotics has recently been granted two separate funding awards by the Welsh Government.
The company was successful in its SMARTCymru 2014-2020- West Wales and the Valleys funding bid for assistance to support its work in developing a first-in-class treatment to manage wound infections. In particular, the work to be carried out in this project will form an integral part of Neem Biotech’s preparation for a first-in-human trial with its selected clinical candidate.
The company’s drug development programme is targeting better management of acute localised or spreading infections that occur in chronic and/or complex wounds. Data generated to date suggest ground-breaking insights into a novel, quorum sensing based approach for how bacterial infections caused by Staphylococcus aureus and Pseudomonas aeruginosa occurring in wounds might be managed.
Neem Biotech were also granted further Capital Funding Support from the Welsh Government’s European Regional Development Fund to assist with procurement of a state-of-the-art 3D confocal imaging microscope to broaden the company’s cell biology capabilities.
Together, these two grants are a significant boost to Neem Biotech’s current research and development outputs and capabilities.
Graham Dixon, Chief Executive Officer of Neem Biotech, said:
We are extremely grateful to the Welsh Government and the European Regional Development Fund for recognising the value of Neem’s work in this way and look forward to continuing to contribute to the Welsh economy and ultimately to the wellbeing of its citizens through the success of our research programmes”.